Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

105 trials with published results (27%)

Research Maturity

275 completed trials (71% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

7.0%

27 terminated out of 385 trials

Success Rate

91.1%

+4.6% vs benchmark

Late-Stage Pipeline

32%

123 trials in Phase 3/4

Results Transparency

38%

105 of 275 completed with results

Key Signals

105 with results91% success27 terminated

Data Visualizations

Phase Distribution

302Total
Not Applicable (26)
Early P 1 (2)
P 1 (58)
P 2 (93)
P 3 (67)
P 4 (56)

Trial Status

Completed275
Unknown66
Terminated27
Withdrawn15
Recruiting1
Active Not Recruiting1

Trial Success Rate

91.1%

Benchmark: 86.5%

Based on 275 completed trials

Clinical Trials (385)

Showing 20 of 20 trials
NCT00200343Phase 3CompletedPrimary

Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C

NCT01466192Phase 3CompletedPrimary

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients

NCT01468584Phase 3CompletedPrimary

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients

NCT00780910Phase 3CompletedPrimary

Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy

NCT00591214Phase 1CompletedPrimary

Safety and PK Study of MP-424 to Treat Chronic Hepatitis C

NCT00199719Phase 2CompletedPrimary

Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAM

NCT06922643Phase 4CompletedPrimary

Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital

NCT01634919CompletedPrimary

Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated with Peginterferon Alpha-2a and Ribavirin

NCT01340573TerminatedPrimary

Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)

NCT06180590RecruitingPrimary

The Efficacy of Vosevi in Treating DAA-experienced Patients

NCT01120795Phase 4CompletedPrimary

Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy

NCT00187473CompletedPrimary

Natural History of Hepatitis C in Patients With Normal Liver Tests

NCT00882193Early Phase 1TerminatedPrimary

Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers

NCT00876174WithdrawnPrimary

Effects of Genotypes on Interferon Signaling in Chronic Hepatitis C

NCT00571714Not ApplicableWithdrawnPrimary

Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients

NCT03612973Not ApplicableCompletedPrimary

Changes in Liver Fibrosis, Lipid Profile and Insulin Resistance in HCV Patients Who Received Antiviral Therapy

NCT05895448Phase 4UnknownPrimary

Treatment of HCV-Infected Recent Injection Drug Users in U.S. Liver Clinics

NCT01439776Phase 4CompletedPrimary

Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients

NCT02545335CompletedPrimary

Neutrophil Function During Therapy With Protease Inhibitors in Chronic Hepatitis C

NCT03993925Active Not RecruitingPrimary

Enhancing Access to Care for Chronic Hepatitis C Infected Populations in Hong Kong

Scroll to load more

Research Network

Activity Timeline